Structure-activity relationships of synthetic analogs of (-)-epigallocatechin-3-gallate as proteasome inhibitors

被引:0
|
作者
Kazi, A
Wang, ZG
Kumar, N
Falsetti, SC
Chan, TH
Dou, QP
机构
[1] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA
[2] Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA
[3] Univ S Florida, Coll Med, Dept Biochem, Tampa, FL 33612 USA
[4] Univ S Florida, Coll Med, Dept Mol Biol, Tampa, FL 33612 USA
[5] McGill Univ, Dept Chem, Montreal, PQ H3A 2K6, Canada
关键词
(-)-EGCG; green tea; organic synthesis; proteasome inhibitors; cell cycle; growth inhibition;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Cancer-related molecular targets of green tea polyphenols, such as (-)-epigallocatechin-3-gallate [(-)-EGCG], remain unknown. We previously showed that ()-EGCG is a potent and specific inhibitor of the proteasomal chymotrypsin-like activity in vitro and in vivo. Materials and Methods: EGCG amides and five simple analogs were prepared by enantioselective synthesis. Proteasome inhibition in vitro was measured by fluorogenic substrate assay and in vivo by accumulation of proteasome target proteins (p27, IkappaB-alpha and Bax). Inhibition of tumor cell proliferation was determined by G(1) arrest, DNA fragmentation and colony formation inhibition. Results: EGCG analogs with modifications in the A-ring, C-ring or ester bond inhibit the chymotrypsin-like activity of purified 20S proteasome with altered potencies. However; these compounds were able to potently inhibit the proteasome activity in vivo and also suppress colony formation of prostate cancer LNCaP cells. Some compounds caused G, arrest and DNA fragmentation in leukemia Jurkat T cells. However, these EGCG analogs caused no or little proteasome inhibition in normal or nontransformed cells. Conclusion: The A-ring and gallate ester/amide bond are essential for the proteasome-inhibitory function of (-)-EGCG.
引用
收藏
页码:943 / 954
页数:12
相关论文
共 50 条
  • [1] Epigallocatechin and epigallocatechin-3-gallate are not inhibitors of tyrosinase
    Gasowska-Bajger, Beata
    Wojtasek, Hubert
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2024, 113
  • [2] Structure-activity study of epi-gallocatechin gallate (EGCG) analogs as proteasome inhibitors
    Wan, SB
    Landis-Piwowar, KR
    Kuhn, DJ
    Chen, D
    Dou, QP
    Chan, TH
    BIOORGANIC & MEDICINAL CHEMISTRY, 2005, 13 (06) : 2177 - 2185
  • [3] Antitumor activity of novel fluoro-substituted (-)-epigallocatechin-3-gallate analogs
    Yang, Huanjie
    Sun, Dong Kui
    Chen, Di
    Cui, Qiuzhi Cindy
    Gu, Yan Yan
    Jiang, Tao
    Chen, Wei
    Wan, Sheng Biao
    Dou, Q. Ping
    CANCER LETTERS, 2010, 292 (01) : 48 - 53
  • [4] Anti-angiogenic Activity and Intracellular Distribution of Epigallocatechin-3-gallate Analogs
    Piyaviriyakul, Suratsawadee
    Shimizu, Kosuke
    Asakawa, Tomohiro
    Kan, Toshiyuki
    Siripong, Pongpun
    Oku, Naoto
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2011, 34 (03) : 396 - 400
  • [5] Structure-activity studies of (-)-epigallocatechin gallate derivatives as HCV entry inhibitors
    Bhat, Rohit
    Adam, Amna T.
    Lee, Jungeun Jasmine
    Deloison, Gaspard
    Rouille, Yves
    Seron, Karin
    Rotella, David P.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (17) : 4162 - 4165
  • [6] The Effect of (-)-Epigallocatechin-3-Gallate on the Aβ Secondary Structure
    Acharya, Atanu
    Stockmann, Julia
    Beyer, Leon
    Nabers, Andreas
    Gerwert, Klaus
    Gumbart, James C.
    Batista, Victor S.
    BIOPHYSICAL JOURNAL, 2020, 118 (03) : 47A - 47A
  • [7] The suppression in osteoclast differentiation and activity by epigallocatechin-3-gallate
    Irie, Yuko
    Iwai, Shinichi
    Amano, Hitoshi
    Oka, Yoshiomi
    Yamada, Shoji
    Oguchi, Katsuji
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2011, 115 : 269P - 269P
  • [8] Analysis of the Antimicrobial Activity of Epigallocatechin-3-Gallate (EGCG)
    Muravieva, V. V.
    Bembeeva, B. O.
    Priputnevich, T. V.
    Kiselev, V. I.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2024, 177 (01) : 88 - 92
  • [9] Structure-activity relationships for synthetic peptide inhibitors of thrombin
    Clement, CC
    Gingold, J
    Philipp, M
    FASEB JOURNAL, 2003, 17 (05): : A1006 - A1006
  • [10] Effects of epigallocatechin-3-gallate combined with ascorbic acid and glycerol on the stability and uric acid-lowering activity of epigallocatechin-3-gallate
    Xie, Qianjin
    Cai, Xiaqiang
    Dong, Xu
    Wang, Ying
    Sun, Minghui
    Tai, Lingling
    Xu, Yan
    PHARMACEUTICAL BIOLOGY, 2021, 59 (01) : 157 - 166